Sort
21,453 grants matching “tuberculosis”
DRUG PHARMACOKINETICS &RISK FACTORS FOR RELAPSE IN RIFAPENTINE TRIAL
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2002 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2002 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2002 · RR
SERUM BANKING FOR EVALUATION OF NEW DIAGNOSTIC AND TREATMENT TECHNOLOGY FOR TB
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2002 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2001 · RR
SERUM BANKING FOR EVALUATION OF NEW DIAGNOSTIC AND TREATMENT TECHNOLOGY FOR TB
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2001 · RR
DRUG PHARMACOKINETICS &RISK FACTORS FOR RELAPSE IN RIFAPENTINE TRIAL
$234,837University Of Texas Hlth Sci Ctr San Ant · M01 · FY2002 · RR
RC#2: Macrophage Oxidant Stress and Dysfunction
$234,833Lou Ann S. Brown · Emory University · P50 · FY2013 · AA
In vitro detection of anti-TB liver metabolites in early drug discovery
$234,820Scott G. Franzblau · University Of Illinois At Chicago · R21 · FY2013 · AI
Evaluating Mycobacterium avium glycopeptidolipids as key factors in the transition from biofilm to macrophages
$234,750Jeffrey Scott Schorey · University Of Notre Dame · R21 · FY2022 · AI
Investigating the molecular requirements for ESX-1-lytic activity in pathogenic mycobacteria
$234,750Patricia A Champion · University Of Notre Dame · R21 · FY2021 · AI
Distinguishing cytosolic sensing of DNA and cyclic dinucleotides in vivo
$234,750Russell E Vance · University Of California Berkeley · R21 · FY2014 · AI
Temporal profiling of the functional phosphoproteome in M. tuberculosis infected
$234,750Sarah A Stanley · University Of California Berkeley · R21 · FY2014 · AI
Identifying the mycobacterial genes controlling bacteriolysis in the macrophage cytoplasm
$234,750Patricia A Champion · University Of Notre Dame · R21 · FY2024 · AI
Animal Core
$234,726John R. Chan · Albert Einstein College Of Medicine · P01 · FY2012 · AI
Mobile Phone-Based Video Directly Observed Therapy for Tuberculosis
$234,721Richard S Garfein · University Of California, San Diego · R21 · FY2010 · AI
Human Immunodeficiency Virus (HIV) and CD4 Lymphopenia Immunopathogenesis
$234,593Irini Sereti · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Epigenetic Study of Resistance to Infection by Mycobacterium tuberculosis
$234,563Yan Sun · Emory University · R21 · FY2021 · AI
Enhancing Research Informatics Capacity for Health Information in Colombia (ENRIC
$234,519Juan Carlos Puyana · University Of Pittsburgh At Pittsburgh · D43 · FY2013 · TW
A novel viral defense system
$234,500Graham F. Hatfull · University Of Pittsburgh At Pittsburgh · R21 · FY2018 · AI
Nrf2 regulation of alveolar macrophage immune responses in vivo to Mycobacterium tuberculosis
$234,497Alissa Chen Rothchild · University Of Massachusetts Amherst · R21 · FY2022 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$234,436Laurie Gill · South Dakota State Dept Of Health · U52 · FY2008 · PS
Role of eosinophils during bacterial infection
$234,430Denise M. Monack · Stanford University · R21 · FY2024 · AI
Minority Health &Health Disparities International Research Training Program
$234,425San Diego State University · T37 · FY2005 · MD
MYCOBACTERIAL ENVIRONMENT WITHIN MACROPHAGES
$234,422Oregon State University · R01 · FY2002 · AI